{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=2", "query": { "condition": "Resected Stage", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resected+Stage&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T10:50:32.944Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01845805", "title": "Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "oral azacitidine", "type": "DRUG" }, { "name": "Observation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2014-01-10", "completion_date": "2021-04-09", "has_results": true, "last_update_posted_date": "2022-10-04", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01845805" }, { "nct_id": "NCT02714374", "title": "GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Organ Cancers" ], "interventions": [ { "name": "GL-ONC1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Andrew Lowy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2016-03-25", "completion_date": "2019-08-06", "has_results": false, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02714374" }, { "nct_id": "NCT03583710", "title": "Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ENSAT Stage I Adrenal Cortex Carcinoma", "ENSAT Stage II Adrenal Cortex Carcinoma", "ENSAT Stage III Adrenal Cortex Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Mitotane", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2018-08-20", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03583710" }, { "nct_id": "NCT03456076", "title": "A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Alectnib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 257, "start_date": "2018-08-16", "completion_date": "2031-11-19", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03456076" }, { "nct_id": "NCT00003089", "title": "Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Lung Cancer" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-07", "completion_date": "2004-02", "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003089" }, { "nct_id": "NCT07049276", "title": "The Multicentre Selective Lymphadenectomy Trial - 3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cutaneous Melanoma, Stage III" ], "interventions": [ { "name": "Index lymph node resection", "type": "PROCEDURE" }, { "name": "Therapeutic lymph node dissection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Melanoma Institute Australia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2025-10-01", "completion_date": "2040-08", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07049276" }, { "nct_id": "NCT00582660", "title": "Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Adenoma", "Colorectal Carcinoma" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "19 Years to 90 Years" }, "enrollment_count": 40, "start_date": "2001-12", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2017-06-15", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00582660" }, { "nct_id": "NCT02193282", "title": "Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage II Lung Non-Small Cell Cancer AJCC v7", "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2015-02-11", "completion_date": "2027-02-03", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 1403, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02193282" }, { "nct_id": "NCT00769379", "title": "Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Ductal Carcinoma In Situ" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Whole Breast Irradiation", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2014, "start_date": "2008-12-10", "completion_date": "2025-06-02", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 1249, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 764 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769379" }, { "nct_id": "NCT06496659", "title": "Segmentectomy After Induction Therapy (SAINT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Segmentectomy" ], "interventions": [ { "name": "Segmentectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 25, "start_date": "2024-08-02", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-07-23T10:50:32.944Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06496659" } ] }